Allosteric modulators of IR that function depending on the presence of insulin would allow patients to use their own insulin more effectively (e.g. in type 2 diabetics), or to inject lower insulin doses (e.g. in type 1 patients), leading to fewer adverse events such as hypoglycemia and body weight gain. Here, INS is linked to type 2 diabetes mellitus.